COVID-19 vaccine GSK

po文清單
文章推薦指數: 80 %
投票人數:10人

關於「COVID-19 vaccine GSK」標籤,搜尋引擎有相關的訊息討論:

GSK: HomeThe homepage of the GSK global corporate website. ... @COP26 as Principal Partner at the 2021 UN #climatechange conference. twitter.com/bmj_latest/sta…Our response to COVID-19 · New GSK · GSK announces major ... · Careers | Our response to COVID-19 | GSKThe use of an adjuvant is of importance in a pandemic situation where there is significant demand for a vaccine, since it may allow more doses to be produced ... twSingapore inks advance purchase deal with GSK for Covid-19 drug ...2021年6月30日 · Mike Crichton, senior vice-president for specialty and primary-care therapy area at GSK, said vaccines, together with treatments like sotrovimab ... | Challenges in ensuring global access to COVID-19 vaccines2021年2月12日 · Several COVID-19 vaccines have now been authorised or approved ... Sanofi with GlaxoSmithKline, Protein subunit, $2·1 billion, US Government.COVID-19 Vaccine Platforms: Challenges and Safety ContemplationsThe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic as of March 2020, creating a global crisis and claiming millions of ...Singapore gives interim authorisation for use of GlaxoSmithKline ...2021年6月30日 · The Pfizer-BioNTech and Moderna COVID-19 vaccines were granted interim authorisation under the route earlier. HSA also granted conditional ... twNanotechnology for COVID-19: Therapeutics and Vaccine Research2020年6月22日 · The current global health threat by the novel coronavirus disease 2019 (COVID-19) requires an urgent deployment of advanced therapeutic ...S.Korea's GL Rapha certified to produce Sputnik COVID-19 vaccines5 天前 · South Korean biotech firm GL Rapha has secured regulatory approval from Russia to produce and market the Sputnik family of coronavirus ...Singapore looking into unusual surge after record COVID-19 cases3 天前 · COVID-19 vaccines not linked to pregnanc ... COVID-19: Delhi records 22 cases, zero d ... EU begins real-time review of Sanofi-GSK.Clover raises $230M as COVID-19 vaccine nears phase 32021年2月23日 · Clover Biopharmaceuticals has raised $230 million to take a COVID-19 vaccine candidate into a phase 2/3 clinical trial.


請為這篇文章評分?


延伸文章資訊